Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.
2.

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60.

PMID:
10931080
3.

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.

Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.

J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52.

PMID:
10852458
4.

Cabergoline therapy for macroprolactinoma during pregnancy: a case report.

Shahzad H, Sheikh A, Sheikh L.

BMC Res Notes. 2012 Oct 31;5:606. doi: 10.1186/1756-0500-5-606.

5.

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.

Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A.

J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22.

PMID:
10404830
6.

The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.

Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.

Pol Arch Med Wewn. 2003 May;109(5):489-95.

PMID:
14768178
7.

Prolactinomas and pregnancy.

Bronstein MD.

Pituitary. 2005;8(1):31-8. Review.

PMID:
16411066
8.

Cabergoline treatment in a case of macroprolactinoma after delivery.

Falsetti L.

Acta Eur Fertil. 1995 May-Jun;26(3):105-7.

PMID:
9098469
9.

Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.

Delgrange E, Maiter D, Donckier J.

Eur J Endocrinol. 1996 Apr;134(4):454-6.

PMID:
8640297
10.

Diagnosis and drug therapy of prolactinoma.

Ciccarelli E, Camanni F.

Drugs. 1996 Jun;51(6):954-65. Review.

PMID:
8736617
11.

Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.

Iyer P, Molitch ME.

Endocr Pract. 2011 May-Jun;17(3):e55-8. doi: 10.4158/EP10369.CR.

PMID:
21324816
12.
13.

Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.

Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F.

J Endocrinol Invest. 1999 May;22(5):354-9.

PMID:
10401709
14.

Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.

Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.

Eur J Endocrinol. 1996 Oct;135(4):413-20.

PMID:
8921822
15.

The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.

Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR.

J Pediatr Hematol Oncol. 2005 Jun;27(6):326-9.

PMID:
15956887
16.
17.

Giant macroprolactinoma and pregnancy.

Saraiva J, Gomes L, Paiva S, Ruas L, Carvalheiro M.

Arq Bras Endocrinol Metabol. 2013 Oct;57(7):558-61.

18.

Chiasmal herniation as a complication of bromocriptine therapy.

Taxel P, Waitzman DM, Harrington JF Jr, Fagan RH, Rothfield NF, Chen HH, Malchoff CD.

J Neuroophthalmol. 1996 Dec;16(4):252-7.

PMID:
8956160
19.

A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.

Berwaerts J, Verhelst J, Abs R, Appel B, Mahler C.

J Endocrinol Invest. 2000 Jun;23(6):393-8. Review.

PMID:
10908167
20.

Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy.

Shanis BS, Check JH.

Gynecol Endocrinol. 1996 Apr;10(2):91-4.

PMID:
8701792
Items per page

Supplemental Content

Write to the Help Desk